



Patent  
Brobeck Dkt No.: 030639.0043.UTL2  
Atty. Docket No.: 238/086 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Beeley, et al.  
Serial No.: PCT/US98/24210 International  
09/554,533 United States  
Filed: November 13, 1998 International  
November 14, 1997 Priority

Confirmation No.: To be assigned  
Group Art Unit: To be assigned  
Examiner: To be assigned

Title: NOVEL EXENDIN AGONIST  
COMPOUNDS

**RECEIVED**

Commissioner of Patents and Trademarks  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

MAY 19 2003

TECH CENTER 1600/2900

Dear Sir:

AMENDMENT TO DIRECT ENTRY

Applicants submit this amendment in response to the Office Action mailed September 26, 2002. Applicants were given a time period of one month from the mailing of this Office Action to comply with the requirements of sequence listing rules. Applicants submit that this amendment is being timely filed to allow a response to be filed up to and including October 28, 2002.

In response to the Office Action, applicants submit herewith a "Sequence Listing" in paper copy and in computer readable form (CRF) as required under 37 CFR 1.821- 1.825. The Sequence Listing is provided in ASCII text on the accompanying diskette.

As required under 37 CFR §1.821(f), the Sequence Listing information recorded in computer readable form is identical to the written Sequence Listing paper copy accompanying this submission.

**CERTIFICATE OF MAILING**  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

October 28, 2002  
Date of Deposit

Linda Reynolds  
Name of Person Mailing Paper  
Linda Reynolds  
Signature of Person Mailing Paper

This Sequence Listing adds no new matter. The paper copy and the computer readable form of the Sequence Listing are identical to the Sequence Listing originally filed in PCT/US98/21210 (the only difference the two applications being the difference in application number, filing date, and the change to inventors as applicants). Entry of the sequence listing and this amendment is respectfully requested.

**AMENDMENT**

**In the Sequence Listings:**


Please add as a new section the Sequence Listings included herein as pages 1-34 and as a diskette having a computer readable form (CRF) included herein.

No fees are believed due with this submission, however, if any fees are due, please charge Amylin Pharmaceuticals, Inc.'s Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC

Date: Oct 28, 2002

  
\_\_\_\_\_  
James W. Collett, Ph.D.  
Registration No.: 46,636